Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Study of GBR 1342, a CD38 / CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma

Multiple Myeloma

The purpose of this study is to determine the safety profile, maximum tolerable dose (MTD) and cohort expansion of single-agent GBR 1342 in subjects with multiple myeloma who have received prior therapies.
Multiple Myeloma
I
Mohan, Sanjay
NCT03309111
VICCHEMP17111

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: